EGFR and non-small cell lung carcinoma: Mutations of V689M and L703F in the JM region were observed in NSCLC patients and constitutively activate mutant EGFR without ligand binding.[11] The mechanism of the possible structural basis is V689 and L703 mutations can stabilize the asymmetric active dimeric form of TKD.